Jagsonpal Pharmaceuticals Limited

NSEI:JAGSNPHARM Stock Report

Market Cap: ₹16.9b

Jagsonpal Pharmaceuticals Management

Management criteria checks 0/4

Jagsonpal Pharmaceuticals' CEO is Manish Gupta, appointed in Jul 2022, has a tenure of 2.5 years. total yearly compensation is ₹26.70M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.29% of the company’s shares, worth ₹371.47M. The average tenure of the management team and the board of directors is 1.9 years and 2.6 years respectively.

Key information

Manish Gupta

Chief executive officer

₹26.7m

Total compensation

CEO salary percentage100.0%
CEO tenure2.5yrs
CEO ownership2.3%
Management average tenure1.9yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Jan 14
Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) As Shares Slide 25%

Jan 14
Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) As Shares Slide 25%

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Oct 14
Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06
Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29
Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13
A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05
Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21
Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08
The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21
Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30
Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

CEO Compensation Analysis

How has Manish Gupta's remuneration changed compared to Jagsonpal Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

₹523m

Sep 30 2024n/an/a

₹243m

Jun 30 2024n/an/a

₹203m

Mar 31 2024₹27m₹27m

₹225m

Dec 31 2023n/an/a

₹245m

Sep 30 2023n/an/a

₹283m

Jun 30 2023n/an/a

₹313m

Mar 31 2023₹11m₹11m

₹267m

Compensation vs Market: Manish's total compensation ($USD309.64K) is above average for companies of similar size in the Indian market ($USD185.26K).

Compensation vs Earnings: Manish's compensation has increased by more than 20% in the past year.

CEO

Manish Gupta (57 yo)

2.5yrs

Tenure

₹26,700,000

Compensation

Mr. Manish Gupta serves as Non-Executive Director at Solara Active Pharma Sciences Ltd. since 2024. He serves as Operating Partner of pharmaceuticals at Convergent Finance LLP since joining the firm in Jul...

Leadership Team

NamePositionTenureCompensationOwnership
Manish Gupta
MD & Director2.5yrs₹26.70m2.29%
₹ 387.2m
Ashish Lakhotia
Chief Financial Officerless than a year₹790.00kno data
Abhishek Joshi
Company Secretary & Compliance Officer1.9yrs₹890.00kno data
Sudeep Paul
Vice President of Sales & Marketingno datano datano data
Bharat Chugh
Assistant General Manager of Human Resourcesno datano datano data

1.9yrs

Average Tenure

Experienced Management: JAGSNPHARM's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Manish Gupta
MD & Director2.5yrs₹26.70m2.29%
₹ 387.2m
Radhika Madhukar Pereira
Independent Director2.6yrs₹900.00kno data
Harsha Raghavan
Non-Executive Chairman2.6yrsno datano data
Rajpal P. Kochhar
Chairman Emeritusno data₹6.81m4.57%
₹ 772.4m
Debasis Nandy
Independent Director2.6yrs₹1.10mno data
Prithipal Kochhar
Non-Executive Director2.6yrsno data0.39%
₹ 65.7m
Pallavi Gupta
Independent Director2.6yrs₹1.00mno data

2.6yrs

Average Tenure

54yo

Average Age

Experienced Board: JAGSNPHARM's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 14:44
End of Day Share Price 2025/01/24 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jagsonpal Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution